Abstract | The dimerization partner, RB-like, E2F and multi-vulval class B (DREAM) complex provides a previously unsuspected unifying role in the cell cycle by directly linking p130, p107, E2F, BMYB and forkhead box protein M1. DREAM mediates gene repression during the G0 phase and coordinates periodic gene expression with peaks during the G1/S and G2/M phases. Perturbations in DREAM complex regulation shift the balance from quiescence towards proliferation and contribute to the increased mitotic gene expression levels that are frequently observed in cancers with a poor prognosis. PERSPECTIVES NATURE REVIEWS | CANCER VOLUME 13 | AUGUST 2013 | 585
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. On receiving appropriate growth factor signalling, a quiescent cell will enter the cell cycle, pass the restriction point and, during the G1 to S phase transition, turn on genes that are required for DNA synthesis (FIG. 1a) . The control of the cell cycle by RB, the product of the RB1 gene, is well established
. However, the control of entry into S phase by RB does not fully account for how gene expression is regulated throughout the cell cycle. For example, it was not understood how RB regulated the expression of 'late' cell cycle genes (such as cyclin B1 (CCNB1)) that are expressed in later phases of the cell cycle (such as G2/M); the mRNA levels of such genes peak during G2/M, and their protein products are required to complete mitosis. In contrast to the cyclical waves of gene expression that are present in cycling cells, the expression of nearly all genes required for DNA synthesis and mitosis is reduced when cells exit the cell cycle and enter into the quiescent or G0 phase in response to differentiation signals or the absence of growth factors.
The ability of RB to promote or to maintain entry into the G0 phase was also not a specific part of the RB cell cycle model (FIG. 1a) . Thus, there has been indirect evidence for additional cell cycle-regulatory pathways that are not reliant on RB.
Recently, several unexpected discoveries revealed that the RB-like pocket proteins p130 (encoded by RB-like 2 (RBL2)) and p107 (encoded by RBL1), together with BMYB (encoded by MYB-like 2 (MYBL2)) and forkhead box M1 (FOXM1), coordinate cell cycle-dependent gene expression through a common pathway. p130 or p107 forms the multisubunit DREAM (dimerization partner (DP), RB-like, E2F and multi-vulval class B (MuvB)) complex, which represses most if not all cell cycle gene expression during quiescence. The MuvB core component of the DREAM complex also coordinates gene expression during S phase and G2/M phase through its interactions with BMYB and FOXM1 (FIG. 1b) . The function of the highly conserved DREAM complex (its components are conserved in vertebrates, flies and worms) is the focus of research in many laboratories.
Disruption of the cell cycle is a wellknown occurrence in cancer, and many of the genes involved in cell cycle regulation, such as MYC, cyclin D1 (CCND1) and RB1, are known to be deregulated, mutated, amplified or lost during tumour progression. Because of these perturbations, understanding the coordination of gene expression during the cell cycle has been a focus of cancer research for many years. Moreover, since BMYB and FOXM1 are overexpressed in a number of tumour types, understanding the function of the DREAM complex and the MuvB core during tumorigenesis has become an area of research interest. In this Opinion article, we discuss DREAM and the MuvB core, their known functions within the cell cycle and the relevance this has for cancer research.
MuvB genes and protein complexes
Caenorhabditis elegans and the synMuv genes. The laboratory of Robert Horvitz 2 identified a signalling pathway in Caenorhabditis elegans that controls vulva development (FIG. 2a) . Loss-of-function mutations in the Vul class of genes leads to the absence of a vulva 2 . Cloning of the Vul genes revealed that they are involved in cellular proliferation and encode homologues of epidermal growth factor (EGF), EGF receptor (EGFR) and RAS, among others [3] [4] [5] . Increased activation of the Vul genes results in multiple vulva-type organs, which are referred to as the multi-vulva phenotype (Muv). In addition, certain combinations of loss-of-function mutations in specific genes also result in worms with the Muv phenotype 6 . These genes were termed synthetic multi-vulva (synMuv). Three classes of synMuv genes, A, B and C, were identified, all of which oppose the EGF-EGFR-RAS signalling cascade that is required for normal vulva development 7 . Although the class A synMuv genes seem to be involved in regulating EGF expression, the class B synMuv genes encode the worm homologues of RB (LIN-35), E2F (EFL-1 and EFL-2) and DP1 (DPL-1) 8, 9 ( FIG. 2a) . In addition, the class B synMuv genes include several genes -lin-54, lin-53, lin-37, lin-9 and lin-52 -with unknown function 10, 11 . The class B genes also contain components of the nucleosome remodelling and deacetylation (NuRD) complex, and the class C genes contain homologues of the lysine acetyltransferase 5 (KAT5; also known as TIP60)-transformation/transcription Nature Reviews | Cancer domain-associated protein (TRRAP) complex 12, 13 , indicating that the regulation of chromatin, and therefore gene expression, is likely to be important for the generation of the Muv phenotype in C. elegans.
Purification of the fly dREAM and MMB complexes. Biochemical studies in Drosophila melanogaster have brought further insight into the function of the uncharacterized worm synMuvB genes. In ovarian follicle cells, repeated rounds of DNA replication amplify genes of the chorion locus 14 . The Botchan laboratory 15 purified a protein complex that could bind specifically to this locus. The complex contained Myb in addition to four Myb-interacting proteins (Mips): Mip130 (a homologue of LIN9); Mip120 (a homologue of LIN54); Mip40 (a homologue of LIN37); and chromatin assembly factor 1 (Caf1; also known as p55, which is a homologue of RB-binding protein 4 (RBBP4)) 15 (FIG. 2b) . Because the Mips have strong homology to the previously uncharacterized worm synMuvB genes, the complex was named Myb-MuvB (MMB). Purification of the native Mip120 and epitope-tagged Mip130 confirmed the presence of Myb, Mip130, Mip40 and Caf1 and also revealed Lin52 and the RB homologues RB-family protein 1 (Rbf1), Rbf2, E2f2 and Dp in the MMB complex 16 . Mutation of Mip130 or RNA interference (RNAi)-mediated knockdown of Mip130, Mip120 or Caf1 led to decreased chorion gene amplification, confirming the role of the MMB complex in this process 17 . In a separate study, a collaborative effort between the Brehm and Dyson laboratories focused on identifying proteins bound to Rbf and E2f in D. melanogaster embryo nuclear extracts 18 . They purified a complex containing Rbf1, Rbf2, Dp, E2f2, Myb and several homologues of proteins encoded by the synMuvB genes, including Mip130, Mip120, Mip40 and Caf1, and they named it the Drosophila RBF, E2f2 and Mip (dREAM) complex 18 . A role for the dREAM complex in gene repression was supported by the observation that RNAi-mediated knockdown of E2f2, Mip130 or Mip120 led to increased expression of E2F target genes that were typically silenced in D. melanogaster cell lines 16, [18] [19] [20] (FIG. 2a) .
Following the identification of the fly MMB and dREAM complexes, a similar complex was immunopurified from C. elegans extracts and named DP, RB and MuvB (DRM). The worm DRM complex contains LIN-9, LIN-35 (a homologue of RB), LIN-37, LIN-52, LIN-53 (a homologue of RBBP4), LIN-54 and DPL-1 (REF. 21 ). Notably, Myb was not purified with the worm DRM complex 7, 21 , which may reflect the absence of an obvious MYB homologue in C. elegans 22 .
Mammalian DREAM and BMYB-MuvB complexes. The identification of the mammalian DREAM complex followed the discoveries of the fly MMB and dREAM complexes and the worm DRM complex. Mammalian LIN9 (the homologue of LIN-9 and Mip130) was identified in silico and found to cooperate with RB in cellular growth suppression assays 23, 24 .
Immunoprecipitation of the RB-like protein p130 followed by mass spectrometry-based identification of associated proteins showed that mammalian cells also contain a large multiprotein complex that consists of E2F4 or E2F5 and their heterodimeric DP partners, as well as LIN9, LIN54, LIN37, LIN52 and RBBP4, which comprise the MuvB core 25 (FIG. 2b) .
Notably, the mammalian p130-containing DREAM complex does not contain a MYB family protein. Immunoprecipitation of individual MuvB core factors followed by mass spectrometry detected the MuvB core, p130, p107, BMYB and AMYB (encoded by MYBL1) 25, 26 . Furthermore, immunoprecipitation of BMYB, a sequence-specific DNA binding factor, co-precipitated all five MuvB core proteins but not p130, p107, E2F4 or DP1. This suggests that the mammalian MuvB core binds to either p130 or p107 to form the DREAM complex or to BMYB to form the BMYB-MuvB complex. These two distinct complexes contrast with the fly MMB complex, which contains both RB and MYB together with the MuvB core The p130-containing DREAM complex is present in serum-starved or quiescent G0 cells, whereas the BMYB-MuvB complex is found in S phase-enriched cell populations [25] [26] [27] . Although several laboratories have shown that p107 can bind to the MuvB core, the exact cell types or conditions in which it binds have not been clearly defined [25] [26] [27] . Similarly, AMYB can bind to the MuvB core, although this may only occur in specific cell types or tissues 25 . Initial studies reported that RB binds to LIN9 and that p107 binds to The activator E2Fs, including E2F1, E2F2 and E2F3, contribute to the expression of the early cell cycle genes during the G1 to S phase transition (indicated by the green arrow). RB may restrict E2F-dependent gene expression during DNA damage signalling or oncogene-induced senescence. The classic model of the RB-E2F pathway depicted here does not account for the expression of late cell cycle genes (grey arrow) during G2/M phase. Perturbations in the RB control of E2F activity occur in most cancer types and include inactivating mutations of the RB1 gene, increased CDK activity owing to overexpression of cyclin D and cyclin E or loss of F-box and WD repeat domain containing 7 (FBXW7), decreased expression of CDK inhibitors such as INK4A and p21, or expression of viral cyclins, such as Karposi's sarcoma herpes virus (KSHV) viral cyclin, which binds to cellular CDKs and renders them resistant to inhibition by CDK inhibitors 132, 133 . In addition, the viral oncoproteins human papilloma virus E7, polyomavirus large T antigen or adenovirus E1A can bind to RB and dissociate it from E2F. b | The central role of the multi-vulval class B (MuvB) core in binding and directing key transcription factors to the promoters of cell cycle genes during various cell cycle phases is shown. MuvB binds p130-E2F4-dimerization partner (DP) to form the DP, RB-like, E2F and MuvB (DREAM) complex in G0 phase and to repress all cell cycle-dependent gene expression. Association of the MuvB core with p130-E2F4 is dependent on dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A)-mediated phosphorylation (P) of the MuvB subunit LIN52. The MuvB core recruits BMYB during S phase and then recruits forkhead box protein M1 (FOXM1) to the promoters of the G2/M phase-expressed genes. In all three instances, the MuvB core is essential for targeting the complexes to specific sets of cell cycle gene promoters.
BMYB, but in our opinion it remains unclear whether these interactions occur at physiological protein expression levels, as these results were obtained with proteins transiently expressed from plasmids 23, 28 . Other evidence indicates that RB has functions that are distinct from the DREAM complex and that p107 binds the MuvB core without BMYB 23, 25, 29, 30 . DREAM controls quiescence DREAM binds E2F-regulated gene promoters in quiescence. The RB-like protein p130 is typically expressed in quiescent mammalian cells. The high levels of p130 expression during quiescence and its ability to bind to the repressive E2F4 and E2F5 transcription factors suggests a role for p130 in repression of E2F-dependent transcription. Indeed, the repression of cell cycle gene promoters in quiescent cells is associated with the recruitment of E2F4 and p130, as well as with low levels of histone acetylation 31 . By contrast, levels of p130 are kept low in proliferating cells owing to ubiquitin-mediated degradation 32 . Genome-wide chromatin immunoprecipitation (ChIP) studies of the mammalian DREAM complex have provided clues about the scope of the activity of this complex. Through the use of ChIP with antibodies specific for p130, E2F4, LIN9 and LIN54 followed by microarray analysis, a significant overlap of binding enrichment for each factor was found at hundreds of sites across the genome 25 . As expected, the binding sites identified for p130 overlap to a large degree with those detected for E2F4, but they also significantly overlap with binding sites for LIN9 and LIN54. Enrichment for one factor at any site is accompanied by similar enrichment for the other components of the DREAM complex. This result implies that p130 and E2F4 bind to promoters together with the MuvB core as an intact DREAM complex. Location analysis and gene ontology analysis revealed that these binding sites are positioned close to the transcription start sites of hundreds of genes in which the level of gene transcription changes during the cell cycle. Notably, genes with peak levels in early (G1/S) or late (G2/M) phases of the cell cycle were included among the DREAM targets. By contrast, ChIP studies of the fly dREAM and MMB complexes in D. melanogaster cell lines revealed a much broader occupancy; close to one-third of all promoters were bound by members that form these complexes 33 . This may reflect a role for the fly dREAM and MMB complexes in gene regulation beyond the cell cycle.
Disruption of various components of the DREAM complex by mutation or RNAi led to the loss of cell cycle-dependent gene repression in G0 phase. Normally, p107 is only expressed in proliferating cells and not during quiescence. However, knockdown or mutation of p130 results in the increased expression of p107 (REFS 25, 34) and the formation of a p107-containing DREAM complex in serum-starved, quiescent cells. However, if the levels of p107 and p130 are simultaneously reduced by knockdown or knockout then the MuvB core is unable to form a functional DREAM complex during quiescence and repression of E2F-dependent genes is lost 25, 30 . This result is consistent with the observation that entry into the cell cycle from G0 phase occurs earlier in p107
−/− double-knockout mouse embryonic fibroblasts (MEFs) than in wildtype cells, and that genes such as Mybl2 and ribonucleotide reductase M2 (Rrm2) are deregulated in these knockout MEFs 34 . In serum-starved, quiescent cells, RNAi knockdown of LIN9 or the combined loss of p130 and p107 also leads to increased cell cycle gene expression 25 . However, Lin9-mutant MEFs arrest normally on serum starvation and enter into S phase with normal kinetics after serum stimulation, indicating than LIN9 is not required for entry into S phase 35 . E2F4 and E2F5 may also complement each other in the DREAM complex. For example, E2f4
−/− double-knockout MEFs re-enter the cell cycle from G0 phase with normal kinetics but fail to arrest in G1 phase in response to the expression of the cyclindependent kinase inhibitor INK4A (encoded by CDKN2A) 36 . The DREAM complex binds to at least two distinct DNA elements in the promoters of cell cycle-dependent genes (TABLE 2) . Through p130, E2F4 and DP1, the DREAM complex binds to E2F-binding sites 25 .
Similarly to the E2F transcription factors, E2F-binding sites have been separated into activator and repressor sites. Although it is not always possible to distinguish between them, distinct repressor and activator E2F-binding sites have been identified for a few cell cycle-dependent gene promoters 37 . In addition to E2F, the MuvB core functions as a sequence-specific DNA-binding factor. It has been known for many years that several genes expressed during late S phase or G2/M phase contain a common sequence in their promoter regions that is known as the cell cycle genes homology region (CHR) element 38 . A DNA-affinity column purification of proteins that bind CHR identified several subunits of the MuvB core complex 39 . Specifically, the LIN54 subunit binds directly to the CHR element in promoters of genes, such as cyclin-dependent kinase 1 (CDK1; also known as CDC2) 39, 40 . For at least some promoters, cell cycle-dependent element (CDE) sites, which may represent special E2F-binding elements, and the CHR elements are in close proximity to each other 38 . An element similar to CHR was found closely situated to E2F sites in the MYBL2 promoter and was named as the downstream repression site (DRS); this probably represents a MuvB-binding site 41, 42 . Given their proximity and the ability of p130-E2F4 to form a stable complex with the MuvB core, it is likely that the specificity and binding affinity of the DREAM complex to promoters is increased when the E2F and MuvB components of the DREAM complex cooperate in binding to more than one sequence element.
DYRK1A-dependent DREAM assembly.
Different signals control the assembly of the DREAM complex and entry into the quiescent phase. Several components of the DREAM complex have been shown to be phosphorylated in cells. In particular, LIN52, the smallest subunit of the MuvB core, has a strikingly variable phosphorylation pattern that is dependent on its interacting partners. When co-immunoprecipitated by p130, LIN52 is always phosphorylated on the S28 residue 30 (FIG. 2b,c) . By contrast, both phosphorylated and non-phosphorylated
Box 1 | RB-mediated cell cycle progression
The control of the cell cycle by RB, the product of the retinoblastoma tumour suppressor gene (RB1), has long been recognized. The central tenet has been that hypo-phosphorylated RB binds to E2F transcription factors during G1 phase and inhibits cell cycle-dependent, E2F-mediated gene expression. RB preferentially binds to the activating E2F transcription factors E2F1, E2F2 and E2F3 with their dimerization partners DP1, DP2 and DP3, respectively, and represses their activity. The activating E2Fs promote the expression of genes required for DNA synthesis during G1/S phase. Phosphorylation by cyclin D-cyclin-dependent kinase 4 (CDK4) and cyclin E-CDK2 releases RB from E2F transcription factors and thereby permits cell cycle gene expression. However, the control of entry into S phase by RB does not fully account for how gene expression is regulated throughout the cell cycle. Nature Reviews | Cancer . These results indicate that the S28 in LIN52 is required for p130 binding to the MuvB core and for DREAM assembly.
Dual specificity tyrosine-phosphorylationregulated kinase 1A (DYRK1A) contributes to phosphorylation of S28-LIN52. Loss or inhibition of DYRK1A reduces the levels of phosphorylated S28-LIN52 and p130 binding to the MuvB core, thereby eliminating the DREAM complex 30 . The DYRK subfamily of protein kinases in mammals has five members 43 . Both DYRK1A and the closely related DYRK1B can phosphorylate S28-LIN52 in vitro, and RNAi knockdown of DYRK1A reduces levels of S28-LIN52 phosphorylation and DREAM complex formation 30 ( FIG. 2c,d ). Consequently, loss of DYRK1A activity would be predicted to compromise quiescence and increase the expression of E2F-dependent genes. DYRK1A catalytic activity directed towards LIN52 can be regulated by the kinases large tumour suppressor 1 (LATS1) or LATS2 (REF. 44 ). Knockdown of LATS1 or LATS2 reduces the ability of DYRK1A to phosphorylate S28-LIN52, compromises p130 binding to the MuvB core and reduces the ability of cells to enter quiescence and senescence 44 . LATS1 and LATS2 are downstream effector kinases in the Hippo tumour suppressor pathway that can phosphorylate the transcriptional co-activator Yes-associated protein 1 (YAP1) [45] [46] [47] . Phosphorylation of YAP1 reduces its ability to activate TEA domain protein 1 (TEAD1), a transcriptional co-activator that promotes cellular proliferation [48] [49] [50] [51] . Therefore, decreased LATS1 and LATS2 activity, and perhaps reduced Hippo signalling, would reduce DYRK1A-mediated DREAM complex assembly and entry into quiescence and permit YAP1 to activate the TEAD proteins to facilitate cell growth.
DREAM and senescence. The DREAM complex is sensitive to disruption by the same growth promoting and oncogenic stimuli as RB (FIG. 1a) . For example, cyclin D-CDK4 can disrupt the DREAM complex by phosphorylation of p130, releasing it from E2F4-DP1 and LIN9. The amino-terminal 84 residues of LIN9 are required for binding to p107 or p130 (REF. 52 ). Expression of a LIN9 mutant lacking this N-terminal region (LIN9-Δ84) bypasses the requirement for CDK4 activity and results in a loss of binding to p107 but maintenance of binding to BMYB. Thus, in Cdk4 −/− cells, the LIN9-Δ84 mutant is able to increase the expression of at least some . In mammalian cells, RB and the dimerization partner, RB-like, E2F and MuvB (DREAM) complex make independent contributions to opposing RAS function. In Drosophila melanogaster, RB-E2F homologues, as well as homologues of several synMuvB genes, are required to repress E2F target genes, which show sex-and differentiation-specific expression patterns. b | A schematic of the domains and overall length of subunits of the MuvB core complex as revealed by a search of the Entrez Conserved Domains database.The cysteine-rich motif domain (CXC) might represent the specific DNA-binding module of LIN54. LIN9 contains a domain in RB-related pathway (DIRP), which is present in many eukaryotic genomes, although its function is unknown. RB-binding protein 4 (RBBP4) and its WD40 domain might recruit other proteins or modified histones. c | The amino acid sequence surrounding the S28 residue in LIN52 is highly conserved across several eukaryotic genomes. d | Shown are the domains that are present in dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), which is the kinase responsible for phosphorylating LIN52 at S28. Caf1, chromatin assembly factor 1; Dp, dimerization partner; D. pseudoobscura, Drosophila pseudoobscura; EGFR, EGF receptor; EPC1, enhancer of polycomb homologue 1; Mip, Myb-interacting protein; NLS, nuclear localization signal; PEST, proline, glutamic acid, serine and threonine; Rbf, RB family protein; TRRAP, transformation/transcription domain-associated protein.
E2F target genes 52 . Viral oncoproteins, such as human papilloma virus (HPV) E7 and SV40 large T antigen, can also disrupt the DREAM complex. For example, levels of the DREAM complex are decreased in the HPV-transformed cervical carcinoma cell lines CaSki and SiHa
53
. RNAi-mediated knockdown of HPV E7 restores DREAM complex formation and induces quiescence in these cells. Importantly, although the DREAM complex cannot be detected in HeLa cells, the MuvB core complex is present and is capable of binding to BMYB 54 . Therefore, viral oncogene binding to p130 disrupts binding to E2F4, DP1 and the MuvB core but does not seem to interfere with BMYB binding to the MuvB core.
Despite these similarities to RB, the DREAM complex may serve a fundamentally distinct role in establishing and maintaining oncogene-induced senescence. Senescence is thought to have a tumour-suppressive function because it is induced as a result of the deregulation of certain oncogenes, such as members of the RAS family 55, 56 . DYRK1A-dependent phosphory lation of S28-LIN52 and recruitment of p130 to the MuvB core to form the DREAM complex is required for RAS-induced senescence in human BJ diploid fibroblasts that are immortalized by overexpression of telomerase reverse transcriptase (TERT) 30 . Inhibition of DYRK1A kinase activity in these cells or expression of S28A-LIN52 can suppress HRAS G12V -induced senescence. By contrast, Lowe and colleagues 29 found that RNAimediated knockdown of RB alone, but not knockdown of p107 and p130, could partially overcome HRAS G12V -induced senescence in the human diploid fibroblast IMR90 cell strain. Although these studies are supportive of the model that RB and the DREAM complex provide distinct functions during senescence, the differences in these studies may reflect differences in the choice of cells. IMR90 cells have a strong dependence on the RB and p53 pathways for the induction of senescence. By contrast, BJ cells have less prominent INK4A expression compared with IMR90 or MRC5 cells, perhaps making them less sensitive to the RB pathway 57 . Studies in mice or specific tissues may bring further insight into the different roles of RB and DREAM.
The switch from DREAM to BMYB-MuvB When cells leave G0 phase and enter into the cell cycle, p130 is dissociated from the repressor E2Fs (E2F4 and E2F5) and the MuvB core, resulting in the release of the DREAM complex from cell cycle-regulated promoters [25] [26] [27] 54, 58 . Activator E2Fs (E2F1, E2F2 and E2F3) are recruited to the promoters of genes with peak expression during the G1 to S phase transition 31 (FIG. 3a) .
These 'early' cell cycle genes encode many factors that are required for DNA synthesis and are a subset of the genes bound by the DREAM complex during quiescence. BMYB is among the many genes repressed by the DREAM complex during quiescence and subsequently expressed during the G1/S transition 25, 59, 60 . BMYB has long been known to bind to the promoters of genes expressed in the G2/M phase, such as CDK1 and CCNB1, and activate their transcription 37 . However, it was recently demonstrated that the binding of BMYB to late cell cycle promoters is dependent on its interaction with the MuvB core, and vice versa. For example, RNAi-mediated knockdown of BMYB or the MuvB core reduced binding of both factors to late cell cycle gene promoters 54 . Consistent with this, both BMYB and the MuvB core bound to DNA probes derived from a target promoter, CCNB2, in a manner dependent on the presence of an intact CHR element in this promoter 39 . Similarly, mutation of MYB binding sites in the survivin (also known as BIRC5) promoter disrupted both LIN9 and BMYB binding 58 . The cooperative binding of BMYB and the MuvB core seems to be independent of p130, E2F4 and the DREAM complex. In cells with little or no DREAM complex, such as rapidly growing embryonic stem cells or HPV E7-expressing cervical cancer cell lines, the BMYB-MuvB complex undergoes cell cycle-dependent binding to the promoters of G2/M phase-expressed genes during S phase 53, 54 .
Loss of BMYB or MuvB leads to G2/M defects. BMYB has been considered a classical, DNA sequence-specific transcription factor. Overexpression of BMYB will activate a promoter-reporter construct containing MYB-binding sites or promoters from a late cell cycle gene (reviewed in REFS 61, 62) . Furthermore, loss of BMYB results in lower levels of late cell cycle or mitotic genes 54, 63 . Importantly, the transactivation activity of BMYB is increased after phosphorylation by cyclin A-CDK2 (REFS 64-67). Accordingly, mutants of BMYB lacking the cyclin A-CDK2 phosphorylation sites are unable to activate transcription 68, 69 . Genetic studies in D. melanogaster and zebrafish also strongly support roles for BMYB in activating mitotic gene expression during G2/M phase 33, [70] [71] [72] and in maintaining chromosomal stability during mitosis [73] [74] [75] . There is an apparent paradox in the role of the MuvB core in the context of its interaction with the BMYB transcription factor. Although the MuvB core is required for p130-mediated repression of E2F-dependent genes during quiescence 25 , it is also required for BMYB-dependent transactivation of the G2/M phase-expressed genes 54, 60, 76 . Notably, loss of Myb in D. melanogaster leads to reduced mitotic gene expression and to adult lethality that can be suppressed by mutations in the MuvB core proteins 17, 72, 77, 78 . These findings suggest that Myb and MuvB work together in D. melanogaster cells to regulate the expression of late cell cycle genes. Given that a Myb mutant lacking a DNA-binding domain can rescue Myb-null mutants, these data also indicate that some functions of Myb might not require its capacity to bind DNA and instead rely on the interaction between Myb and MuvB 72 . Given that BMYB, but not AMYB and MYB, can substitute for Myb in D. melanogaster cells, these findings might be relevant to mammalian BMYB-MuvB interactions 78 . In mammalian cells, mutation or decreased expression of BMYB or MuvB core components results in decreased levels of G2/M phase-expressed genes accompanied by a mitotic arrest. For example, conditional knockout of Lin9 in mice leads to embryonic lethality: cells enter S phase with normal kinetics but are unable to complete mitosis 35 . In cell lines, knockdown of MuvB components results in the reduced expression of late cell cycle genes, including CCNB1, CDK1, ubiquitin-conjugating enzyme E2C (UBE2C; also known as UBCH10), centro mere protein E (CENPE) and polo-like kinase 1 (PLK1), with little effect on the expression levels of early cell cycle genes, such as cell division cycle 6 (CDC6) and ribonucleotide reductase M1 (RRM1) 26, 54, 76 . Similarly, knockdown of LIN9 or BMYB results in mitotic arrest in F9 embryonal carcinoma cells, which is accompanied by decreased levels of B-type cyclins and BIRC5 (REF. 58 ). Depletion of LIN54 also resulted in decreased levels of late cell cycle genes, culminating in cyto kinesis defects and mitotic arrest 79 . Expression of a mutant form of LIN54 containing point substitutions in the DNA-binding, cysteine-rich (CXC) domain inhibited cell cycle progression and decreased expression of some G2/M phase-expressed genes 40, 80 . These results are consistent with the model that BMYB cooperates with the MuvB core to bind to late cell cycle gene promoters and to activate their transcription.
This model does not fully explain how late cell cycle gene expression is regulated. For example, phosphorylation of BMYB is required for its transactivation activity, but it is also required for its ubiquitylation and proteasome-mediated degradation 54, 81 ( FIG. 3a) . Although the presence of phosphorylated BMYB on the PLK1 promoter correlates with the start of PLK1 mRNA expression, there is little BMYB remaining at the point in G2 when maximal levels of PLK1 mRNA are detected 54 . Recent studies now suggest that an additional transcription factor, FOXM1, cooperates with BMYB and the MuvB core to transactivate the late cell cycle genes 54, 82, 83 .
MuvB sequentially recruits BMYB and FOXM1. Several independent lines of evidence in the literature have suggested a potential link between BMYB and FOXM1. The two transcription factors have several target genes in common, including CCNB1, PLK1 and Aurora kinase A (AURKA), which are required for progression into mitosis 76, 84, 85 . BMYB and FOXM1 also share common modalities of regulation; their levels are repressed in G0 phase by the DREAM complex and increased during S phase 25, 59, 86 , and they become activated as a result of multisite phosphorylation by cyclin A-CDK2 and other kinases 69, 87 . Both BMYB and FOXM1 undergo cell cycle-dependent, ubiquitinmediated proteasome degradation. BMYB degradation during G2 phase requires a cullin 1 (CUL1)-dependent E3 ligase activity 81 , whereas FOXM1 degradation occurs later during mitosis in an APC/C (anaphasepromoting complex; also known as the cyclosome)-cadherin 1 (CDH1)-dependent manner 88 . In addition, remarkably similar phenotypes have been observed with the loss of FOXM1, BMYB or MuvB. For example, loss of FOXM1 results in delayed entry into mitosis along with abnormal mitosis and cytokinesis 84 . Knockout of Foxm1 in mice results in a block to proliferation with defects in mitosis 85 . FOXM1 may also be required to prevent DNA re-replication, particularly in mouse hepatocytes and cardiomyocytes 89 .
One of the first demonstrations of a connection between MYB and FOXM1 came from a network analysis that aimed to identify master regulators of B lymphocyte proliferation. This study demonstrated a synergistic activity between MYB and FOXM1, and also showed that the expression of FOXM1 was dependent on MYB 90 . Although MYB is preferentially expressed in cells of the haematopoietic lineage, it is not known whether MYB, in a similar way to BMYB, can bind to the MuvB core 91 . In the same year, another study implicated BMYB in the regulation of FOXM1 expression in embryonic stem cells 92 . More recent studies have strengthened the link between BMYB and FOXM1. A ChIP-sequencing experiment for genes bound by BMYB and MuvB found de novo enrichment for MYB-, FOXM1-and CHRbinding sites in late cell cycle genes, suggesting the possibility of co-regulation by all three factors 54 . RNAi knockdown of BMYB, FOXM1 or MuvB proteins reduces late cell cycle gene expression, resulting in delayed cell cycle progression 54, 84 . Conditional knockout of BMYB reduces late cell cycle Notably, the combined RNAi knockdown of BMYB, FOXM1 and MuvB has no additive effect on late cell cycle gene expression, suggesting that these three factors act through a common pathway 54 . In addition, the MuvB core binds to FOXM1 and is required for the recruitment of FOXM1 to promoters 54, 83 . Strong evidence that supports cooperative binding between BMYB and FOXM1 was provided by the observation that mutation of the MYB-binding site in the BIRC5 promoter eliminates FOXM1 and LIN9 recruitment, as well as BMYB binding, and leads to reduced peak gene expression during G2 and mitosis 82 . These findings agree with the findings that BMYB, in addition to the MuvB core, is required for FOXM1 binding to promoters 54, 82 . FOXM1 seems to act downstream of BMYB, with MuvB serving as a bridge linking these two factors. For example, knockdown of the BMYB or MuvB proteins reduces the binding of FOXM1 to late cell cycle promoters, whereas knockdown of FOXM1 does not affect BMYB or MuvB binding to each other or to late cell cycle promoters 54 . In addition, the MuvB core first binds to BMYB during S phase and then to FOXM1 during G2. However, binding of BMYB and FOXM1 to the MuvB core or binding of BMYB and FOXM1 to late cell cycle promoters do not seem to be mutually exclusive. ChIP-ReChIP experiments revealed that FOXM1 can bind to same promoter simultaneously with BMYB and the MuvB core 54 (FIG. 3a) .
How might BMYB and the MuvB core aid in the recruitment of FOXM1 to promoters? The binding of MuvB and BMYB to their cognate target sequences may increase target specificity for FOXM1 DNA binding. This might explain why the BMYB-, FOXM1-and CHR-binding elements are co-enriched in several mitotic gene promoters 54 . Interestingly, the FOXM1 DNA-binding domain has an unusually low affinity for its consensus sequence TAAACA 93 ; hence FOXM1 may require cooperative binding with BMYB and MuvB to be specifically recruited to its target promoters. In support of this model, a recent report has demonstrated that the CHR element is required for FOXM1 binding to the promoters of genes that are expressed late in the cell cycle 83 . Thus, similar to the requirement for MYB-binding sites, FOXM1 also requires CHR sites for binding to late cell cycle promoters 82, 83 . Although BMYB and MuvB recruit FOXM1 to the late cell cycle promoters, full activation of its transcriptional activity requires PLK1-dependent phosphorylation 94 .
The transcriptional role of BMYB in higher eukaryotes is still unclear, thus its function along with the MuvB core is still to be fully established. Recruitment of FOXM1 to BMYB-MuvB may enable BMYB degradation and thereby relieve MuvB-mediated repression of the late cell cycle genes (FIG. 3a,b) . In an alternative scenario, BMYB and FOXM1 may cooperate in a feedforward loop to activate gene expression. However, this scenario does not explain why BMYB is degraded before the start of mitosis. Perhaps, in a manner similar to MYC, transactivation activity and ubiquitin-mediated degradation of BMYB are tightly linked 95 .
DREAM disruption in cancer
Changes to cell cycle gene levels are the most frequently observed differences when expression profiles of normal tissue samples and cancer tissue samples are compared 96 . Increased levels of cell cycle genes probably at least partly reflect tumours containing a higher fraction of proliferating cells and a lower fraction of terminally differentiated cells compared with normal tissue 97 . However, not all tumours have a high fraction of proliferating cells and not all cell cycle genes are overexpressed in tumours, indicating that, for at least some tumours, there may be deregulation of specific cell cycle genes. Not surprisingly, given their central role in promoting late cell cycle gene expression, BMYB and FOXM1, as well as some of their gene targets including BUB1, PLK1, AURKA and DNA topoisomerase 2α (TOP2A), are frequently overexpressed in tumours and form part of the proliferation Figure 3 | Tipping the balance from quiescence to proliferation in cancer. a | The differential regulation of early and late cell cycle gene expression is shown. At least two major peaks of cell cycle gene expression can be discerned during the cell cycle, and these occur during G1/S phase (indicated by the green line) and during G2/M phase (grey line). The DREAM (dimerization partner (DP), RB-like, E2F and multi-vulval class B (MuvB)) complex represses both early and late cell cycle gene expression during quiescence (red line). Activator E2Fs are required for the expression of G1/S phase-expressed genes, and the MuvB core complex, BMYB and forkhead box protein M1 (FOXM1) are required for the expression of G2/M phase-expressed genes. BMYB and FOXM1 undergo phosphorylation (P) and ubiquitin-dependent destruction by the proteasome during S to G2 phase and M to G1 phase transitions, respectively. Repressor E2Fs, including E2F6-DP, E2F7 and E2F8, contribute to the repression of early or late cell cycle genes, particularly after DNA damage 121, 123, [134] [135] [136] . b | Factors that are overexpressed or amplified (*) or lost ( ‡ ) in cancers are indicated. The net effect results in the loss of DREAM function and increased activity of BMYB-MuvB-FOXM1, driving cells out of quiescence and towards proliferation. APC/C, anaphase-promoting complex (also known as the cyclosome); CDH1, cadherin 1; DYRK1A, dual specificity tyrosine-phosphorylation-regulated kinase 1A; LATS, large tumour suppressor; PLK1, polo-like kinase 1. signature that is characteristic of high-grade tumours with poor prognosis 1, 98 . For example, high levels of MYBL2 are associated with poor prognosis in breast cancer 99 . 101 . In addition, LIN9 is one of the 70 genes that constitute the MammaPrint (Agendia) breast cancer profile that is used to predict risk for metastasis 102 . Even though high BMYB levels are typically associated with poor outcomes, low levels of BMYB have also been associated with cancer. Zebrafish with mutations in bmyb have mitotic defects, as well as an increased risk for developing cancer 75 . Mice that are haploinsufficient for Mybl2 develop various myeloid disorders, including a myelodysplastic syndrome (MDS) and myeloid leukaemia 103, 104 . MYBL2 is present in the 20q locus, which is frequently deleted in human MDS 105, 106 . Although the precise mechanism by which low levels of BMYB expression translate into abnormal myeloid cell proliferation is unclear, it is likely to involve the role of BMYB in regulating cell cycle-dependent gene expression.
Increased expression of FOXM1 has been associated with poor outcomes in many types of cancers. FOXM1 overexpression is correlated with poor prognosis in glioblastoma 107 , prostate 108 , lung 109 , oesophagus 110 , pancreas 111 , breast 112 and ovarian 113 cancers. Interestingly, FOXM1 is part of the chromosomal instability 70 (CIN70) and CIN25 gene signatures that are characteristic of aneuploid tumours 114 . Although BMYB is not part of the CIN signatures, several genes regulated by the BMYB-MuvB complex are over-represented in the CIN70 and CIN25 signatures 54, 114 . It is not known whether overexpression of BMYB and FOXM1 reflects specific deregulation owing to oncogenic mutations and copy number alterations or whether it is due to their central role in controlling late cell cycle gene expression in rapidly growing tumours. Overexpression of BMYB and FOXM1 could potentially alter the balance between DREAM and BMYB-MuvB complexes in a cell. BMYB and FOXM1 levels may be high in cells in which the function of the DREAM complex is compromised though the loss of p130 or p107 (REF. 25 ), DYRK1A 30 , LATS1 or LATS2 (REF. 44 ). It has been reported that BMYB overexpression can rescue senescence that is induced by an activated RAS oncogene in rodent cells 115 . Alternatively, oncogenic mutations that promote entry into quiescence could increase tumour cell survival. For example, DYRK1B is frequently amplified and overexpressed in high-grade serous ovarian carcinoma 116, 117 . It is possible that high levels of DYRK1B could increase DREAM formation by phosphorylation of S28-LIN52. Such quiescent tumour cells might be more resistant to the effects of cytotoxic chemotherapy, which mainly targets cycling cells, as well as to other stresses.
The balance between the DREAM and the BMYB-MuvB complexes can be influenced by p53. Recent studies have demonstrated that activation of p53 in cells treated with DNA-damaging agents leads to increased p130-DREAM occupancy and decreased BMYB binding at late cell cycle gene promoters 118, 119 . This p53-mediated shift in favour of DREAM is dependent on p21 (REFS 118, 119) . The p53-dependent induction of p21 can inhibit cyclin A-CDK2-dependent activation of BMYB and FOXM1 and can reduce p130 phosphorylation, thereby shifting the balance from BMYB-MuvB to DREAM (FIG. 3b) . The G2/M phase-expressed genes with CHR elements in their promoters, including CDK1, CDC25C and CCNB1, seem to be regulated by p53-mediated reactivation of the DREAM complex 118 . It is possible that when DNA-damaged cells undergo a G2/M phase arrest, BMYB-MuvB is replaced by DREAM on late cell cycle promoters 118, 120 . Indeed, re-entry into the cell cycle and progression through M phase after DNA damage requires re-expression of BMYB, suggesting the possibility that DREAM is bound to early promoters and subsequently becomes deactivated to enable expression of BMYB 118 . In this context, it will be important to determine whether DREAM-mediated repression contributes to the tumour-suppressive function of p53.
Conclusions and perspectives
The MuvB core provides an integrative control point for cell cycle-dependent gene expression. The MuvB core contains five proteins -LIN9, LIN37, LIN52, LIN54 and RBBP4 -that remain together throughout the cell cycle and alternately bind to at least three different factors that are involved in transcription at distinct periods of the cell cycle. The MuvB core binds to p130 and the E2F4-DP1 transcription factor during quiescence to repress the expression of hundreds of cell cycle-dependent genes. On entry into the cell cycle, p130 dissociates from the MuvB core and from E2F promoters, thereby permitting the activating E2Fs to transactivate the early (G1/S) cell cycle genes. The MuvB core sequentially recruits BMYB during S phase and then FOXM1 during G2 phase to promote the expression of the late (G2/M) cell cycle genes. The switch from DREAM to BMYB-MuvB is highly regulated. At a minimum, the CDKs disrupt the interaction of p130 with the MuvB core and promote BMYB-MuvB activation. Opposing this, DYRK1A, and perhaps DYRK1B, have an essential role in enabling the binding of p130 to the MuvB core to form the DREAM complex and to permit exit from the cell cycle into quiescence.
The balance between the quiescent DREAM complex and the proliferative phase BMYB-MuvB-FOXM1 complex is frequently perturbed in cancer. Deregulated cyclin and CDK activity disrupts DREAM as well as RB, resulting in derepression of the E2F-dependent cell cycle genes and activation of the late cell cycle genes. Loss of E2F6 (REF. 121 ) and the atypical E2F7 (REF. 122 ) and E2F8 repressor E2Fs, which oppose activator E2F-induced transcription, may provide yet another means of increasing early cell cycle gene expression. Alternatively, decreased levels of BMYB owing to gene loss or increased DREAM formation owing to DYRK1A or DYRK1B overexpression might result in cancer cells exiting the cell cycle and remaining dormant. Although RB may serve a distinct role in repressing activator E2F-dependent transcription, it is not clear whether the loss of RB and the perturbation of DREAM can be distinguished in cancer. This leaves open the question of whether there are separate roles for RB and DREAM during quiescence, during oncogene-induced senescence and in cancers.
Beyond quiescence and senescence, there are many unanswered questions regarding the role of the MuvB core and the DREAM and the BMYB-MuvB-FOXM1 complexes in cell cycle regulation. The structure of the it is not clear whether the loss of RB and the perturbation of DREAM can be distinguished in cancer.
MuvB core is unknown. Although phosphorylated S28-LIN52 is required for the interaction of MuvB with p130, additional requirements for the interaction of the MuvB core with BMYB and FOXM1 are still unknown. It is also unclear whether the MuvB core directly contributes to promoter activation or repression or whether additional factors, such as chromatinremodelling enzymes or modified histones, cooperate with the MuvB core to control cell cycle gene expression in mammalian cells, as suggested by genetic studies in the worm and fly. Perhaps biochemical techniques that combine crosslinking with mass spectrometry will identify additional specific binding factors 126 . Alternatively, reconstitution of the MuvB core complex in vitro using chromatinized templates may address these important questions.
It is also not clear whether the MuvB core regulates gene expression beyond the cell cycle. Studies in D. melanogaster have revealed a role for MMB-dREAM in olfactory receptor gene expression 127 , the expression of programmed cell death genes in neural tissues 128 and the repression of germline gene expression in intestinal tissues 129 . Perhaps isolation of the DREAM and the BMYB-MuvB complexes from distinct mammalian tissues will reveal functions in addition to cell cycle control 130, 131, 142 . It is not known how the D. melanogaster Myb-MuvB complex contributes to chorion gene amplification 15 , and it remains to be determined whether and how Myb and the MuvB core contribute to DNA replication in the fly or in mammalian cells. Interestingly, although aberrant DNA replication has been observed in Mybl2-knockout MEFs 103 , it is unclear whether this is the outcome of a direct role of BMYB in DNA replication. There is some evidence that signalling from DNA damage influences the balance between the DREAM and the MYB-MuvB complexes 118 , although the molecular details remain unknown. A related question is whether the timing of BMYB degradation is regulated by specific events such as the completion of DNA synthesis or signalling from DNA damage checkpoints. Identifying the E3 ubiquitin ligase responsible for targeting BMYB to the proteasome could provide insight into how a cell recognizes the end of S phase and the start of G2 phase.
In terms of cancer research, it will be important to determine whether quiescence and the DREAM complex have an important role in tumour biology. If so, do DYRK1A or DYRK1B function as tumour suppressors? Moreover, in a similar context, does the Hippo tumour suppressor pathway regulate LATS1 and LATS2 activity in terms of the phosphorylation of DYRK1A and DREAM assembly? Identifying tumours with a loss of DYRK1A or LATS may reveal a role for quiescence in tumour suppression. At a basic level we also need to understand how oncogenic perturbations in cell cycle regulators affect DREAM and the MuvB core and whether they differentially perturb RB and the DREAM complex. Given the frequency of FOXM1 overexpression in cancer, it is important to determine whether its contribution to poor prognosis is due to its ability to promote late cell cycle gene expression or whether this reflects additional activities. Last, although targeting oncogenic transcription factors is challenging, BMYB, FOXM1 and MuvB could be susceptible to novel therapeutics owing to their extensive post-translational modifications.
